Previous studies in Caucasians with progressive systemic sclerosis (PSS) have suggested associations of antitopoisomerase I (antitopo I) autoantibodies with either serologically defined HLA-DR2 or DR5. To better define class II HLA associations with the antitopo I response, 161 PSS patients (132 Caucasians and 29 American blacks) were studied for antitopo I autoantibodies by immunodiffusion and immunoblotting, and their HLA-DRB1, DRB3, DQA1, and DQB1 alleles were determined by restriction fragment length polymorphic analysis and DNA oligotyping. Among Caucasians with antitopo I, HLA-DR5(DRB1*1101-*1104), DRB3*0202 and DQw3 (DQw7,8,9) were significantly increased in frequency. In American blacks, however, only HLA-DQB1 *0301 (DQw7) was significantly increased. The presence of HLA-DQB1 *0301 (DQw7) and other HLA-DQB1 alleles bearing the uncharged polar amino acid residue tyrosine at position 30 of the outermost domain was found in all antitopo I-positive Caucasian PSS patients compared with 66% of antitopo I-negative PSS patients (pc = 0.007) and 70% of normal controls (pc = 0.008), as well as all antitopo I-positive black patients. The association with HLA-DQB1 was independent of HLA-DR5(DRB1*1101-*1 104) or any other HLA-DRB1, DRB3, or DQA1 alleles. Alternative or additional candidate epitopes for this autoimmune response include alanine at position 38 and threonine at position 77 of these same DQB1 alleles. These data suggest that genetic predisposition to the antitopo I response in PSS is associated most closely with the HLA-DQB1 locus. (J. Clin. Invest. 1992. 90:973-980.)
Introduction
The cause of progressive systemic sclerosis (PSS),' or scleroderma, is as yet unknown, although both genetic and environ-1. Abbreviations used in this paper: ACA, anticentromere autoantibodies; antitopo I, antitopoisomerase I; OR, odds ratio; PC, corrected P value; PCR, polymerase chain reaction; PSS, progressive systemic sclerosis; RFLP, restriction fragment length polymorphism. mental factors have been implicated (1) (2) (3) (4) (5) (6) (7) . A number of studies have reported associations of HLA antigens with PSS, including MHC class I specificities: HLA-A9 (8, 9) , B8 (10, 11 ) , and B35 (12, 13) ; MHC class II specificities: HLA-DR 1 (13) (14) (15) (16) , DR3 (ll, 17) , and DR5 (16, (18) (19) (20) ; and MHC class III specificities: C4 null alleles (12, 19) . These associations have varied among different centers, with some groups unable to show any HLA associations with PSS (21) (22) (23) (24) (25) .
PSS is a disease in which several highly disease-specific autoantibodies have been defined, which in turn are associated with certain clinical features (26, 27) . These include anticentromere autoantibodies (ACA), occurring predominantly in the CREST variant or mild scleroderma (26) (27) (28) (29) (30) (31) (32) (33) ; antinucleolar autoantibodies, including anti-PM-Scl, associated with the presence of myositis in PSS patients (34) ; and antitopoisomerase I (antitopo I), otherwise known as anti-Scl-70, which correlates with widespread skin involvement and systemic disease (26, 27, 35) . Several recent reports have correlated autoantibody subsets more strongly with certain MHC-class II alleles, including ACA with HLA-DR 1 (27, 36) , DR4 (36) , DR5 (DRw 1) (20) , and DRw8 (36); anti-PM-Scl with HLA-DR3 (36) ; and antitopo I with HLA-DR2 (25) and DR5 (DRwI 1) (27, 36) . Few studies, however, have examined the expanded polymorphism at the molecular level now recognized for the adjacent HLA-DQ loci, although one study reported an increased frequency of HLA-DQw7 in patients with ACA (20) .
Using restriction fragment length polymorphisms (RFLPs) and oligonucleotide typing of class II MHC alleles, we have reported recently that HLA-DQB1 alleles possessing a polar amino acid (either tyrosine or glycine) at position 26 of the outermost domain constitute the strongest association with the ACA autoimmune response in PSS patients (37) . In the present study, we used the same techniques in a large number of PSS patients to compare HLA-DRB1, DRB3, DQA1, and DQB 1 alleles in antitopo I-positive and -negative PSS patients and controls to show that the antitopo I response also is correlated most closely with specific HLA-DQB 1 from Miami, as well as 9 from Georgia who were part of an epidemiological study reported previously (38 Genetic analysis ofHLA-DRBI, DRB3, DQAJ, and DQBI alleles.
Genomic DNA was extracted from peripheral blood leukocytes (41) . "Broad" HLA-DR specificities (DR1, DR2, DR3/6, DR4, DR5(DRwll), DR5(DRwl2), DR7, DRw8, DR9, and DRw1O) were determined either by RFLP analysis of Taq I, Bam HI and Eco RI digested genomic DNA described previously (42) or by polymerase chain reaction (PCR) amplification of 0.5 gg of genomic DNA using the primers DRBAMP-A (5'-CCCCACAGCACGTTTCTTG-3') and DRBAMP-B (5'-CCGCTGCACTGTGAAGCTCT-3'). The PCR was carried out for 30 cycles under the following parameters: denaturation 1 min at 96°C, annealing I min at 55°C, extension 2 min at 72°C. Hybridization and washing conditions were as described previously (43 DRw6(DRw13, 14) , and DRw8 by RFLP or oligotyping underwent group-specific PCR amplification of DRB1 alleles using the primers DRBAMP-3 (5'-CACGTTTCTTGGAGTACTCTAC-3') and DRBAMP-B under conditions outlined for DRBAMP-A and B, except the annealing step for the PCR was at 60°C for 30 s. HLA-DRl and DR4 subtypes were determined by group-specific amplification of HLA-DRBl alleles using the primers DRBAMP-l (5'-TTCTTGTGGCAGCTTAAGTT-3') and DRBAMP-4(5'-GTTTCTTGGAGCAGGTTAAAC-3') along with DRBAMP-B under the same PCR conditions (37) . HLA-DRB3(DRw52) alleles were determined by PCR amplification with the primers DRBAMP-52 (5'-CCCAGCACGTTTCTTGGAGCT-3') and DRBAMP-B. HLA-DR2-DRB1 alleles were determined as has been described elsewhere (43 Where an association with a particular specificity had been reported previously, the P value was not corrected. Odds ratios (OR) were also determined from the same 2 x 2 tables.
Results

Scleroderma-related autoantibody frequencies. Of the 132
Caucasians with PSS examined, antitopo I autoantibodies were found in 21 (16%). No significant differences occurred in the frequencies of antitopo I in Caucasian patients from Houston, Ottawa, and Miami. On the other hand, antitopo I antibodies were found in 38% of the 29 American blacks with PSS, a frequency that was significantly increased in blacks compared with Caucasians, as we have reported previously (54). All but three of the patients with antitopo I were positive by both immunodiffusion and immunoblotting, with three being positive by immunoblotting only. ACAs were found in only one black PSS patient, a frequency significantly less than the 36% seen in Caucasians (54).
Clinical differences between autoantibodysubgroups. Medical records were retrospectively reviewed in 126 (95%) of the 132 Caucasians with PSS. Differences in clinical features between the autoantibody subsets of PSS are shown in Table I . Proximal/diffuse scleroderma (skin involvement proximal to the metacarpophalangeal joints) and interstitial pulmonary disease were significantly less frequent in Caucasians with ACA than in PSS patients lacking this autoantibody (the latter reflecting what has been observed elsewhere [32 ] ).
Among 28 American blacks in whom medical records were reviewed, diffuse or proximal scleroderma and interstitial pulmonary fibrosis were slightly more frequent in those with antitopo I than in those without, although the differences were not significant, perhaps because of the small numbers examined (clinical data were not available on the one black with ACAs).
HLA class IIfrequencies in Caucasians. All but five Caucasian PSS patients and 10 controls had sufficient genomic DNA available for oligotyping. In the few remaining patients and controls, HLA-DRB 1, DQA1, and DQB1 alleles were determined by RFLP analysis, with alleles being assigned by linkage disequilibrium with characteristic RFLP patterns (44). HLA-DR and DQ specificities and alleles did not differ significantly between those with or without proximal/diffuse scleroderma (data not shown). HLA-DQw5 was marginally decreased in those with interstitial pulmonary fibrosis (24 vs. 48% in those without, P = 0.02 uncorrected). This probably reflected the fact that HLA-DQw5 was weakly associated in this group with ACAs (55 vs. 31 % in ACA-negative PSS patients, P = 0.01 uncorrected, and vs. 34% in controls, P = 0.008 uncorrected), which were nearly absent in those with interstitial pulmonary fibrosis. No significant differences in HLA-DR or DQ frequencies were found in those with renal or gastrointestinal involvement or pulmonary hypertension, although the small numbers of patients in these groups (< 10 in each) prevented meaningful statistical analysis.
The frequencies of HLA-DR2 ( DRB 1 * 1501-* 1602), DR4(DRB1 *0401-*0405) and DR5(DRw1 1) (DRBl*1 101-* 1104) were increased in Caucasian PSS patients with antitopo I compared with either PSS patients lacking antitopo I or ACAs (other PSS patients in Tables II and III) or controls, although only the broad specificity HLA-DR5 (DRB *1 10 1-*1 104) achieved statistical significance. It should be noted that ACApositive PSS patients were considered separately because ofthe association of this autoantibody response also with HLA-DQB 1 *0301 (DQw7) (37) (Table III) .
Oligotyping for subtypes of HLA-DR5 (DRwl 1) showed equivalent frequencies ofDRB 1*1 10 1-*1 104 in antitopo I positives and race-matched controls (Table II) . Similarly, HLA-DR2(DRB 1 * 1501-1602) and DR4(DRB 1*040 1-*041 11) subtypes did not differ significantly between antitopo I-positive patients and racially matched controls.
HLA-DQB1 *0301 (DQw7) was increased in frequency in Caucasians with antitopo I compared with other PSS patients (P = 0.02), as well as to Caucasian controls (P = 0.009), although these comparisons did not withstand correction for the number of variables examined (n = 8) (Table III) . HLA-DQB 1 *0302 (DQw8) and DQB 1 *0303 ( DQw9) were also in- after correcting for the eight HLA-DQ specificities examined (57% in antitopo I-positive vs. 29% in other PSS patients (pc = 0.01) and 26% in controls [pc = 0.0004, OR = 3.8]). HLA-DQAl alleles were of similar frequency in antitopo I-positive PSS patients, other PSS patients, and controls (Table III), as were HLA-DPB 1 allele frequencies (55) . HLA-DRB3*0202(DRw52b) was also slightly increased in frequency in antitopo I-positive (52%) compared with antitopo I-negative PSS patients (32%, P = NS) and controls (21%, pc = 0.0 12) (data not shown). No differences in the frequencies of HLA-DR5(DRw1l), DQBI*0301(DQw7), and DQw3 were seen between patients from Texas, Ottawa, or Florida (data not shown).
HLA-class IIfrequencies in American blacks. All American black PSS patients and controls were typed for HLA class II alleles by oligotyping. Neither the extent of skin involvement nor the presence of interstitial pulmonary fibrosis correlated with HLA-DR or DQ specificities among American black PSS patients with antitopo I. On the other hand, the broad specificities HLA-DR4 (DRB 1 *0401, *0403, *0407) and DR5 (DRB * 110 1-* 1104) were both increased in frequency in black antitopo I-positive patients compared with other PSS patients or black controls, although not significantly so, perhaps because of the small number of black PSS patients (Table IV) . HLA-DR5 (DRwl 1) and DR4 subtype frequencies did not significantly differ in the antitopo I-positive patients from that in the other PSS patients or controls. HLA-DQB 1*0301 (DQw7), however, was associated with the antitopo I response compared with both antitopo I-negative PSS patients and controls (Table V). Of the two HLA-DQB1 *0301 (DQw7)-negative American black PSS patients, one had HLA-DQBI*0501 (DQw5) and DQB1 *0602(DQw6) and the other had HLA-DQB1 *0201 (DQw2) and DQB1 *0402(DQw4). HLA-DQB1* 0602(DQw6) was actually decreased in frequency in antitopo I-positive vs.-negative PSS patients, although not significantly.
Localization ofsusceptibility to antitopo I to specific HLA-DQBI sequences. As shown above, most of the Caucasian and American black PSS patients had HLA-DQB 1 *0301 (DQw7), *0302(DQw8), or *0303(DQw9), which all constitute the broad specificity HLA-DQw3. Examination of the amino acid sequences of these alleles (Table VI) showed extensive amino acid sequence homology. The presence of HLA-DQB 1 *0601 -*0604(DQw6) or DQw4 in all antitopo I-positive patients who were negative for HLA-DQw3, as well as the decreased frequencies of HLA-DQw5 and DQw2. 1, suggests an amino acid sequence shared by HLA-DQB1 alleles comprising HLADQw3, DQw4, and DQw6 specificities but not found in those One, a tyrosine residue at position 30 (tyr-30) , is shared by HLA-DQB 1 *0402, *0601, *0602, as well as by DQB1 *0301, *0302, and *0303. An HLA-DQB1 allele bearing tyr-30 was present in 100% of antitopo I-positive Caucasians compared with 66% of other PSS patients and 70% of Caucasian controls (pc < 0.01 in both cases). HLA-DQBl-tyr-30 was likewise found in 100% of American black antitopo I-positive PSS patients. The allelic frequency of HLA-DQB1-tyr-30 was also slightly more frequent in American blacks with antitopo I (80%) versus black PSS patients without antitopo I (61%), although this difference was not statistically significant, perhaps because of the small numbers studied.
Alternatively, other polymorphic amino acids residues are shared by these HLA-DQBl alleles, including methionine in position 14, alanine in position 38, and threonine in position 77. Each of these occurred in 100% of the antitopo I-positive Caucasians (Table VII) and blacks. Unlike tyrosine at position 30, however, none of these residues was statistically significantly increased in antitopo I-positive patients compared with other PSS patients and normal controls. Nonetheless, a role for one or more of these residues in susceptibility to this autoimmune response cannot be excluded. The association of antitopo I with HLA-DQB 1 rather than HLA-DRB 1 or DRB3 alleles is further underscored by examining antitopo I-positive versus -negative PSS patients and controls who were negative for HLA-DR5 (DRwl 1). The allelic frequency of HLA-DQB 1 *0301 (DQw7) was 21% in 17 HLA-DR5 (DRwl 1)-negative, antitopo I-positive Caucasian and American black PSS patients compared with 9% in antitopo I-negative PSS patients and 10% in race-matched controls (P = NS for both groups). The allelic frequency of the broader specificity HLA-DQw3 was 47% in HLA-DR5 (DRwl 1 )-negative Caucasian and American black antitopo I-positive PSS patients compared with 20% in antitopo I-negative patients (P = NS) and 25% in controls (P = 0.04). On the other hand, HLA-DQBI-tyr-30-bearing alleles occurred in 68% of 34 HLA-DR5 (DRwl 1)-negative, antitopo I-positive patient haplotypes compared with 40% of 142 antitopo I-negative PSS patient haplotypes (P = 0.03) and 60% of control haplotypes (P = NS). Evaluation ofa possible HLA-DR5 (DRwl 1 ) association independent of HLA-DQBl *0301 (DQw7), DQw3, or DQB l-tyr-30 was complicated by the finding that only two PSS patients had an HLA-DR5-bearing allele not associated with HLA-DQB 1*0301(DQw7), one with HLA-DQB I *0602(DQw6) (antitopo I positive) and another with HLA-DQB 1*0201 (DQw2) (antitopo I negative).
That HLA-DQ and not DR genes represent the primary MHC class II association with the antitopo I response is further suggested by the presence of HLA-DQB 1 *0301 (DQw7) in all three native American Choctaw PSS patients found to have antitopo I. Two were homozygous for HLA-DQB1 *0301 (DQw7) and the third had this allele and DQw4. Only one of these had HLA-DR5(DRwI 1). Instead, two had HLA-DQB 1 *0301 (DQw7) associated with the rare DRB 1 * 1602 subtype of HLA-DR2.
Discussion
Our data suggest that the broad specificity HLA-DQw3 is most strongly associated with the antitopo I response. HLA-DQw3 comprises HLA-DQB 1*0301 (DQw7) (linked to HLA-DR5 (DRwl 1) as well as other DR specificities), DQw8 (associated with HLA-DR4), and DQw9 (associated with HLA-DR9 and occasionally HLA-DR7) (56) . The HLA-DQB 1 alleles comprising HLA-DQw3 share striking sequence homology (Table VI) . All remaining HLA-DQw3-negative antitopo I-positive PSS patients had HLA-DQw6 (specifically HLA-DQBl*0602), which is found on HLA-DR2(DRB1* 1501) haplotypes (among others), or DQw4, associated in Caucasians with HLA-DRw8 ( DRB 1 *0801, *0802) and in blacks with HLA-DRw8 and HLA-DR3 (DRBl *0302). HLA-DQw3 (DQB 1 *0301, *0302, and *0303), DQw6 (DQB 1 *0602), and DQw4 (DQB 1*0402) share specific amino acid residues not found in the same position on other HLA-DQB 1 alleles. In the second hypervariable region, for example, there is a polar uncharged tyrosine residue at position 30 (tyr-30) , as opposed to a polar uncharged serine or a positively charged histidine. At position 38 there is a hydrophobic alanine (ala-38) as opposed to a hydrophobic valine residue. In the third hypervariable region there is a polar uncharged threonine at position 77 (thr-77) as opposed to a positively charged arginine. Analysis ofthe frequencies of alleles bearing these residues suggests the strongest association ofthese to be with tyr-30 alleles. Thus although HLA-DQw3 (especially the DQB 1*0301 (DQw7) subtype thereof) is most strongly associated with the antitopo I response, the ubiquity of tyr-30-bearing DQB1 alleles in HLADQw3 negatives suggests that HLA-DQB1 -tyr-30 may form the minimum requirement for the antitopo I response. We cannot exclude the possibility, however, that one or more of the other shared polymorphic sequences in DQB 1 alleles may also play important roles.
These data, then, allow a reinterpretation ofprevious apparently conflicting reports of serologically defined HLA class II allele frequencies in PSS. Differences in autoantibody frequencies in the different patient groups reported could explain at least in part some of these discrepancies. For example, reports ofan increased frequency of HLA-DR I (13-16) could be from patient populations with a higher frequency ofACA, or associations with HLA-DR3 (and perhaps even C4 null alleles, which are linked to HLA-DR3 [11, 17, 19] ) could reflect a higher frequency of anti-PM-Scl. Other reports showing associations with HLA-DR5 (16, (18) (19) (20) could be explained by a higher proportion of patients with antitopo I and/or ACA.
Apparent discrepancies of HLA-DR associations with autoantibody subsets of PSS also could be better explained by their linkage disequilibrium with certain HLA-DQ alleles, which in fact may be the primary associations. For example, different reports have linked the ACA response to HLA-DR 1 alone (27) , DRl, DR4, and/or DRw8 (36) , and DR5(DRwll) (20) . These HLA-DR specificities share no common unique amino acid sequences (57) . However, DNA analyses from our own laboratory (37) have shown stronger associations ofACA with HLA-DQB 1 alleles in linkage disequilibrium with these HLA-DR antigens: HLA-DQw5 (linked to HLA-DRI); HLA-DQBI *0301 (DQw7) (found on most HLA-DR5 and many DR4-bearing haplotypes) (54), and HLA-DQw4 (found on most Caucasian HLA-DRw8 haplotypes). These HLA-DQ specificities have in common the presence of a polar amino acid residue at position 26 of the HLA-DQB1 outermost domain and have been found in all of the ACA-positive patients studied thus far (37) .
Similarly, for the antitopo I response, the previous serologic HLA associations have been with HLA-DR2 (25) and DR5 (27, 36) , which share no unique amino acid sequences (57) ; however, HLA-DQB 1 *0602(DQw6) and HLA-DQB 1 *0301 (DQw7), which are in linkage disequilibrium with these DR specificities, respectively (55), share sequence homologies in their second and third hypervariable regions of the HLA-DQB 1 outermost domain. These uniquely shared amino acid residues in these regions were found in all of the antitopo I-positive PSS patients.
The only patient with both ACA and antitopo I antibodies in this study was found to have HLA-DQw4, a specificity that possesses a polar amino acid at DQB 1 position 26 and a tyrosine at DQB 1 position 30. Interestingly, HLA-DQB 1 *0301 (DQw7) also possesses both ofthese potentially relevant DQB 1 sequences and is increased in frequency in both ACA-positive and antitopo I-positive PSS patients, yet both autoantibodies rarely coexist in the same patient (27) . An explanation for this near mutual exclusivity of autoantibody expression is not apparent, however, it suggests a role for non-HLA factors, either genetic or environmental, in triggering these autoimmune responses.
Still, there were some PSS patients who had HLA-DQB-tyr-30 alleles and did not express antitopo I, although the converse was not found. One possible reason could be that the serum level of antitopo I antibodies they expressed were below those detectable by our immunodiffusion and immunoblotting assays. Altematively, these patients may have lacked the appropriate T cell receptor genes to whose products the HLA-DQ heterodimers could present the processed antitopo I autoantigen. Another alternative would be that the HLA associations are better explained by clinical subsets of PSS, which are themselves associated with antitopo antibodies. This was not found, however, in this study.
Finally, these data regarding antitopo I antibodies, as well as our previous studies ofACA, suggest that scleroderma, similar to systemic lupus erythematosus (58) , can be viewed as a composite disease of several HLA-DQ-associated autoantibody (and in turn clinical) subsets. Additional direct evidence that HLA-DQ mediates these autoimmune responses is needed, as well as studies to determine whether these highly specific autoantibodies participate in the pathogenesis of PSS.
